UNSPSC 51112901: Amifostine

This classification denotes a cytoprotective agent with the molecular formula C5H15N2O3PS.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M487QF2F4V, chemically known as 2-((3-aminopropyl)amino)-ethanethiol, dihydrogen phosphate ester (9ci) but more generally known as amifostine, which bears US NIH Compound Identifier 2141. Amifostine most often comes in base, ethiofos, and hyrdate forms. European Medicines Agency schedules Amifostine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12846MIG.

UNSPSC 51112901 Amifostine is a Commodity code covering a specific chemotherapy pharmaceutical agent used in oncology and radiation-protection applications. State and local governments procure amifostine primarily through health system pharmacy departments, Medicaid agencies, and correctional health services when treating eligible cancer patients or managing radiation therapy side effects. The Texas Health and Human Services Commission's April 2026 Request for Information regarding direct-to-manufacturer prescription programs indicates that state pharmacy benefit programs are exploring alternative supply channels beyond traditional pharmacy benefit managers and wholesalers to manage pharmaceutical costs and improve access to specialty drugs, including cytoprotective agents like amifostine. This suggests that state Medicaid programs and health agencies are actively evaluating direct contracting mechanisms with pharmaceutical manufacturers to negotiate net pricing and outcomes-based agreements for pharmaceutical procurement.

The recent activity under this code centers on Texas, where the Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for implementing direct-to-manufacturer prescription programs. The RFI represents preliminary market intelligence rather than a formal competitive solicitation, with the state gathering information from vendors about their capacity to establish direct contracts with self-insured health plans and state agencies, negotiate based on net pricing models without rebates, and implement value-based agreements. No award value, contract duration, or formal evaluation criteria were specified in the RFI materials, indicating that Texas HHS is in the foundational planning stage before issuing a formal RFP with established financial and temporal parameters. The exploratory nature of this procurement vehicle suggests that state health agencies view direct manufacturer relationships as a potential pathway to cost management and improved access for specialty pharmaceuticals, though no binding solicitations have followed the RFI as of the posting date.